These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
371 related items for PubMed ID: 31708652
1. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines. Thomas CM, Asa SL, Ezzat S, Sawka AM, Goldstein D. Curr Oncol; 2019 Oct; 26(5):338-344. PubMed ID: 31708652 [Abstract] [Full Text] [Related]
2. Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation. Qi XP, Lin GB, Chen B, Li F, Cao ZL, Zheng WH, Zhao JQ. Endocr Metab Immune Disord Drug Targets; 2021 Oct; 21(3):554-560. PubMed ID: 32660411 [Abstract] [Full Text] [Related]
3. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin. Zhou Q, Yue S, Cheng Y, Jin J, Xu H. Exp Toxicol Pathol; 2017 Oct 02; 69(8):575-579. PubMed ID: 28552629 [Abstract] [Full Text] [Related]
6. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Maia AL, Siqueira DR, Kulcsar MA, Tincani AJ, Mazeto GM, Maciel LM. Arq Bras Endocrinol Metabol; 2014 Oct 02; 58(7):667-700. PubMed ID: 25372577 [Abstract] [Full Text] [Related]
8. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan. Suzuki A, Hirokawa M, Takada N, Higuchi M, Ito A, Yamao N, Hayashi T, Kuma S, Miyauchi A. Endocr J; 2017 Nov 29; 64(11):1099-1104. PubMed ID: 28883261 [Abstract] [Full Text] [Related]
10. Critically evaluated key points on hereditary medullary thyroid carcinoma. Zhang D, Liang N, Sun H, Frattini F, Sui C, Yang M, Wang H, Dionigi G. Front Endocrinol (Lausanne); 2024 Nov 29; 15():1412942. PubMed ID: 38919477 [Abstract] [Full Text] [Related]
11. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Thyroid; 2016 Dec 29; 26(12):1744-1751. PubMed ID: 27673361 [Abstract] [Full Text] [Related]
12. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Trimboli P, Giovanella L. Clin Chem Lab Med; 2015 Sep 01; 53(10):1507-14. PubMed ID: 25781697 [Abstract] [Full Text] [Related]
16. Hereditary medullary thyroid carcinoma syndromes: experience from western India. Diwaker C, Sarathi V, Jaiswal SK, Shah R, Deshmukh A, Thomas AE, Prakash G, Malhotra G, Patil V, Lila A, Shah N, Bandgar T. Fam Cancer; 2021 Jul 01; 20(3):241-251. PubMed ID: 33392850 [Abstract] [Full Text] [Related]
17. [RET pro-oncogene and medullary thyroid carcinoma]. Wang Y, Du LL, Hou SH, Han CZ, Zhao XW, Wang WG, Xu XQ, Jing JX. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov 07; 51(11):873-876. PubMed ID: 27938622 [Abstract] [Full Text] [Related]
18. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen. Woliński K, Kaznowski J, Klimowicz A, Maciejewski A, Łapińska-Cwojdzińska D, Gurgul E, Car AD, Fichna M, Gut P, Gryczyńska M, Ruchała M. Endokrynol Pol; 2017 Nov 07; 68(4):434-437. PubMed ID: 28585679 [Abstract] [Full Text] [Related]